<DOC>
	<DOC>NCT02332642</DOC>
	<brief_summary>This pilot clinical trial aims at evaluating immuno-modulating effects of palliative treatment with specifically dosed standard chemotherapeutics in patients with metastatic melanoma (AJCC stage IV) by assessing myeloid-derived suppressor cells' (MDSCs) count and activity.</brief_summary>
	<brief_title>Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy</brief_title>
	<detailed_description />
	<criteria>histologically defined metastatic melanoma patients (AJCC stage IV) aged 18 to 80 years at least one prior systemic antimelanoma therapy; if BRAFV600 positive, at least one prior BRAFi therapy therapynaive patients any contraindications for (specific) systemic chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>